Add this result to my export selection Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) - guidance (TA662) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 25 November 2020 NICE is unable to make a recommendation on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung cancer in adults because AstraZenec Read Summary Type: Guidance (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer - guidance (TA660) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 25 November 2020 Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease Read Summary Type: Guidance (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma - guidance (TA658) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 18 November 2020 Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults Read Summary Type: Guidance (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Carfilzomib for previously treated multiple myeloma - guidance (TA657) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 18 November 2020 Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults Read Summary Type: Guidance (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Siponimod for treating secondary progressive multiple sclerosis - guidance (TA656) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 18 November 2020 Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults Read Summary Type: Guidance (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Galcanezumab for preventing migraine - guidance (TA659) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 18 November 2020 Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults Read Summary Type: Guidance (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma - guidance (TA666) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 16 December 2020 Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults Read Summary Type: Guidance (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura - guidance (TA667) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 16 December 2020 Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic Read Summary Type: Guidance (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer - guidance (TA668) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 06 January 2021 Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in Read Summary Type: Guidance (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia - guidance (TA663) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 09 December 2020 Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults Read Summary Type: Guidance (Add filter) Type: Medicines Current Awareness (Remove filter)